Methylene blue (Basic Blue 9) hydrate 是一种鸟苷酸环化酶 (sGC)，单胺氧化酶 A (MAO-A) 和 NO 合酶 (NOS) 抑制剂。Methylene blue hydrate 是一种血管加压剂，在医疗中通常用作染料。Methylene blue hydrate 通过一氧化氮合成酶/鸟苷酸环化酶信号通路降低脉冲前抑制。Methylene blue hydrate 是一种氧化还原循环化合物，能够穿过血脑屏障。Methylene blue hydrate 是Tau 聚集抑制剂。亚甲蓝可减轻脑水肿，减弱小胶质细胞活化，减少神经炎症。
| 生物活性 | Methylene blue (Basic Blue 9) hydrate is aguanylyl cyclase (sGC),monoamine oxidaseA (MAO-A)andNO synthase(NOS)inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue hydrate through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue hydrate is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue hydrate is a Tau aggregation inhibitor. Methylene blue hydrate reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation[1][2][3]. |
体外研究
(In Vitro) | Methylene blue (Basic Blue 9) hydrate (4.5 μM; BV2 microglia) alters the immune profile of LPS-activated BV2 microglia and decreased the level of CD14, IL-1β, TNF-α, and CCL2 mRNA[3].
|
体内研究
(In Vivo) | Methylene blue (Basic Blue 9) hydrate (50 and 100 mg/kg; i.p.; once, for 25 min; male NMRI mice) reduces absent prepulse inhibition[1].
Methylene blue hydrate (20 and 40 mg/kg; p.o.; daily, for 6 months; CaMKIIα-tTA transactivator mice) preserves cognition in mice expressing full-length pro-aggregant human Tau[2].
Methylene blue hydrate (2 mg/kg; i.v.; once, for 1 d; TBI-treated male BALB/c mice) reduces TBI-induced edema and neuroinflammation and reduces acute depression-like behavior[3].
Methylene blue hydrate (2 mg/kg; i.v.; once, for 1 d; TBI-treated male BALB/c mice) reduces the percentage of inflammatory factor[3].
| Animal Model: | Male NMRI mice[1] | | Dosage: | 50 and 100 mg/kg | | Administration: | Intraperitoneal injection; once, for 25 minutes | | Result: | Reduced the prepulse inhibition and reduced the increase in locomotor activity caused by phencyclidine (PCP). |
| Animal Model: | CaMKIIα-tTA transactivator mice[2] | | Dosage: | 20 and 40 mg/kg | | Administration: | Oral administration; daily, for 6 months | | Result: | Inhibited Tau aggregation in CaMKIIα-tTA transactivator mice. |
| Animal Model: | TBI-treated male BALB/c mice[3] | | Dosage: | 2 mg/kg | | Administration: | Intravenous injection; once, for 1 day | | Result: | Decreased the level of CD14, IL-1β, TNF-α, and CCL2 mRNA. |
| Animal Model: | TBI-treated male BALB/c mice[3] | | Dosage: | 2 mg/kg | | Administration: | Intravenous injection; once, for 1 day | | Result: | Reduced the percentage of myeloid (CD11b+/GR1+) cells, reduced IL-1β and enhanced IL-10 expression in microglia. |
|
| Clinical Trial | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
m.cnreagent.com